Postpartum ambulatory and home blood pressure monitoring in women with history of preeclampsia: Diagnostic agreement and detection of masked hypertension

Nuckols, Virginia; Stroud, Amy; Armstrong, Matthew K.; Brandt, Debra; Santillan, Mark K.; Santillan, Donna A.; Pierce, Gary L.

doi:10.1016/j.preghy.2022.05.003

Cited by 3 publications

(2 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This form of hypertension, though difficult to detect, should be suspected in patients with kidney dysfunction or other hypertension-mediated organ damage diagnosed prepregnancy or in the first half of pregnancy [6]. In those high-risk women, out-of-office BP measurements should be recommended; however, screening for masked hypertension should not be routinely performed because the prognostic value in pregnancy remains uncertain [14][15][16].…”

Section: Classification Of Hypertensive Disorders In Pregnancymentioning

confidence: 99%

Management of hypertensive disorders in pregnancy: a Position Statement of the European Society of Hypertension Working Group ‘Hypertension in Women’

Thomopoulos,

Hitij,

De Backer

et al. 2024

Journal of Hypertension

View full text Add to dashboard Cite

Hypertensive disorders in pregnancy (HDP), remain the leading cause of adverse maternal, fetal, and neonatal outcomes. Epidemiological factors, comorbidities, assisted reproduction techniques, placental disorders, and genetic predisposition determine the burden of the disease. The pathophysiological substrate and the clinical presentation of HDP are multifarious. The latter and the lack of well designed clinical trials in the field explain the absence of consensus on disease management among relevant international societies. Thus, the usual clinical management of HDP is largely empirical. The current position statement of the Working Group ‘Hypertension in Women’ of the European Society of Hypertension (ESH) aims to employ the current evidence for the management of HDP, discuss the recommendations made in the 2023 ESH guidelines for the management of hypertension, and shed light on controversial issues in the field to stimulate future research.

show abstract

Section: Classification Of Hypertensive Disorders In Pregnancymentioning

confidence: 99%

Management of hypertensive disorders in pregnancy: a Position Statement of the European Society of Hypertension Working Group ‘Hypertension in Women’

Thomopoulos,

Hitij,

De Backer

et al. 2024

Journal of Hypertension

View full text Add to dashboard Cite

show abstract

“…63,69 Some have also suggested that home-based BP monitoring could be implemented as a screening tool for masked or white-coat hypertension when used either before or complementary with ambulatory BP monitoring based on data showing moderate-to-high agreement between BP measurements obtained from these techniques during 1 to 4 years postpartum. 70 More data are needed to identify the prevalence of masked and white-coat hypertension during the immediate postpartum period.…”

Section: Opportunities For Hypertension and Cvd Prevention During The...mentioning

confidence: 99%

Chronic Hypertension in Pregnancy: A Lens Into Cardiovascular Disease Risk and Prevention

Cameron¹,

Everitt

Lee³

et al. 2023

Hypertension

View full text Add to dashboard Cite

Hypertension is a major, modifiable risk factor for cardiovascular disease (CVD) in the United States. Over the past decade, the prevalence of chronic hypertension (CHTN) during pregnancy has nearly doubled with persistent race- and place-based disparities. Blood pressure elevations are of particular concern during pregnancy given higher risk of maternal and fetal morbidity and mortality, as well as higher lifetime risk of CVD in birthing individuals with CHTN. When identified during pregnancy, CHTN can, therefore, serve as a lens into CVD risk, as well as a modifiable target to mitigate cardiovascular risk throughout the life course. Health services and public health interventions that equitably promote cardiovascular health during the peripartum period could have an important impact on preventing CHTN and reducing lifetime risk of CVD. This review will summarize the epidemiology and guidelines for the diagnosis and management of CHTN in pregnancy; describe the current evidence for associations between CHTN, adverse pregnancy outcomes, and CVD; and identify opportunities for peripartum care to equitably reduce hypertension and CVD risk throughout the life course.

show abstract

Clinical practice guidelines for the care of girls and women with Turner syndrome

Gravholt,

Andersen,

Christin-Maitre

et al. 2024

European Journal of Endocrinology

View full text Add to dashboard Cite

Turner syndrome affects 50 per 100,000 females, affects multiple organs through all stages of life, necessitating multidisciplinary care. This guideline extends previous ones and includes important new advances, within diagnostics and genetics, estrogen treatment, fertility, co-morbidities, and neurocognition and neuropsychology. Exploratory meetings were held in 2021 in Europe and US culminating with a consensus meeting in Aarhus, Denmark in June 2023. Prior to this, eight groups addressed important areas in TS care: 1) diagnosis and genetics, 2) growth, 3) puberty and estrogen treatment, 4) cardiovascular health, 5) transition, 6) fertility assessment, monitoring, and counselling, 7) health surveillance for comorbidities throughout the lifespan, and 8) neurocognition and its implications for mental health and well-being. Each group produced proposals for the present guidelines, which were meticulously discussed by the entire group. Four pertinent questions were submitted for formal GRADE (Grading of Recommendations, Assessment, Development and Evaluation) evaluation with systematic review of the literature. The guidelines project was initiated by the European Society for Endocrinology and the Pediatric Endocrine Society, in collaboration with members from the European Society for Pediatric Endocrinology, the European Society of Human Reproduction and Embryology, the European Reference Network on Rare Endocrine Conditions, the Society for Endocrinology, and the European Society of Cardiology, Japanese Society for Pediatric Endocrinology, Australia and New Zealand Society for Pediatric Endocrinology and Diabetes, Latin American Society for Pediatric Endocrinology, Arab Society for Pediatric Endocrinology and Diabetes, and the Asia Pacific Pediatric Endocrine Society. Advocacy groups appointed representatives for pre-meeting discussions and the consensus meeting.

show abstract

Postpartum ambulatory and home blood pressure monitoring in women with history of preeclampsia: Diagnostic agreement and detection of masked hypertension

Cited by 3 publications

References 44 publications

Management of hypertensive disorders in pregnancy: a Position Statement of the European Society of Hypertension Working Group ‘Hypertension in Women’

Management of hypertensive disorders in pregnancy: a Position Statement of the European Society of Hypertension Working Group ‘Hypertension in Women’

Chronic Hypertension in Pregnancy: A Lens Into Cardiovascular Disease Risk and Prevention

Clinical practice guidelines for the care of girls and women with Turner syndrome

Contact Info

Product

Resources

About